Literature DB >> 23254129

Clinical laboratory experience with cervista HPV HR as a function of cytological classification: comparison with retrospective digene HC2 high-risk HPV DNA test data.

Brian K Du Chateau, Elizabeth R Schroeder, Erik Munson.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23254129      PMCID： PMC3592064          DOI： 10.1128/JCM.02836-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  10 in total

1.  Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media.

Authors:  Ted E Schutzbank; Charlene Jarvis; Nicole Kahmann; Katherine Lopez; Marlea Weimer; Aleta Yount
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

2.  Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.

Authors:  Mark H Einstein; Mark G Martens; Francisco A R Garcia; Daron G Ferris; Amy L Mitchell; Stephen P Day; Marilyn C Olson
Journal:  Gynecol Oncol       Date:  2010-05-21       Impact factor: 5.482

3.  Clinical laboratory evaluation of Invader® chemistry and hybrid capture for detection of high-risk human papillomavirus in liquid-based cytology specimens.

Authors:  Erik Munson; Brian K Du Chateau; Bronya Bellerose; Jolanta Czarnecka; Judy Griep
Journal:  Diagn Microbiol Infect Dis       Date:  2011-09-06       Impact factor: 2.803

Review 4.  Special commentary: patient safety and the next generation of HPV DNA tests.

Authors:  Walter Kinney; Mark H Stoler; Philip E Castle
Journal:  Am J Clin Pathol       Date:  2010-08       Impact factor: 2.493

5.  A comparison of two methods to determine the presence of high-risk HPV cervical infections.

Authors:  Lawrence R Johnson; Cindi R Starkey; James Palmer; James Taylor; Spencer Stout; Stephanie Holt; Ryan Hendren; Brian Bock; Elizabeth Waibel; Gale Tyree; Gerald C Miller
Journal:  Am J Clin Pathol       Date:  2008-09       Impact factor: 2.493

6.  Human papillomavirus genotype specificity of hybrid capture 2.

Authors:  Philip E Castle; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

Review 7.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.

Authors:  Silvia de Sanjosé; Mireia Diaz; Xavier Castellsagué; Gary Clifford; Laia Bruni; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Infect Dis       Date:  2007-07       Impact factor: 25.071

8.  Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA.

Authors:  C C Ginocchio; D Barth; F Zhang
Journal:  J Clin Microbiol       Date:  2008-03-26       Impact factor: 5.948

9.  Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay.

Authors:  Anna K Wong; Raymond C-K Chan; W Stephen Nichols; Shikha Bose
Journal:  J Clin Microbiol       Date:  2008-01-03       Impact factor: 5.948

Review 10.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.

Authors:  Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661
  10 in total
  4 in total

1.  Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.

Authors:  Aniek Boers; Rong Wang; Lorian Slagter-Menkema; Bettien M van Hemel; Hilde Ghyssaert; Ate G J van der Zee; G Bea A Wisman; Ed Schuuring
Journal:  J Clin Microbiol       Date:  2014-10-08       Impact factor: 5.948

2.  Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid.

Authors:  Erik Munson; Lynn Kroeger; Sandra Balzer; Robert Amrhein; Kimber L Munson; Maureen Napierala; Richard Hudspeth; Patrick J Dillon
Journal:  J Clin Microbiol       Date:  2013-11-06       Impact factor: 5.948

3.  A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.

Authors:  Gerd Boehmer; Lisa Wang; Angelika Iftner; Barbara Holz; Juliane Haedicke; Reinhard von Wasielewski; Peter Martus; Thomas Iftner
Journal:  BMC Infect Dis       Date:  2014-12-09       Impact factor: 3.090

4.  Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.

Authors:  Aniek Boers; Lorian Slagter-Menkema; Bettien M van Hemel; Jerome L Belinson; Teus Ruitenbeek; Henk J Buikema; Harry Klip; Hilde Ghyssaert; Ate G J van der Zee; Geertruida H de Bock; G Bea A Wisman; Ed Schuuring
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.